344940-45-0

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule of the compound.
2. Heterocyclic compound

Explanation

A compound containing a ring of atoms with at least one atom being a non-carbon atom.
3. Diazepane ring

Explanation

A seven-membered ring containing four carbon atoms and three nitrogen atoms.
4. Aminopyridine group

Explanation

A pyridine ring (a six-membered aromatic ring with one nitrogen atom) with an additional amine group (-NH2) attached.
5. BOC group (tert-butyloxycarbonyl)

Explanation

A protecting group for amines, which temporarily blocks the amine group's reactivity during chemical reactions.

Explanation

The compound can be used as a building block for the synthesis of pharmaceuticals and other bioactive molecules.
7. Unique structure and functional groups

Explanation

The compound's structure and functional groups make it a versatile intermediate for creating diverse chemical compounds for various biological and pharmaceutical purposes.

Potential applications

Medicinal chemistry

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 1227862-58-9 5'-amino-4-phenyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-ol 
• 112275-50-0 tert-butyl 1,4-diazepine-1-carboxylate 

Relevant academic research and scientific papers

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I).

Diacylglycerol Acyltransferase Inhibitors

Provided herein are compounds of the formula (1): as well as pharmaceutically acceptable salts thereof wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type 11 diabetes mellitus and metabolic syndrome.

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ( DGAT ) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: (We bring to your attention that the illustrative compound of the invention is not provided on this electronic version as it is provided in the abstract of the paper copy)